First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
10.1177/1758835919836374
Saved in:
Main Authors: | Park, Keunchil, Lim, Darren Wan-Teck, Okamoto, Isamu, Yang, James Chih-Hsin |
---|---|
Other Authors: | DUKE-NUS MEDICAL SCHOOL |
Format: | Review |
Language: | English |
Published: |
SAGE PUBLICATIONS LTD
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/218616 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Tan, Wan-Ling, et al.
Published: (2022) -
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
by: Chang, Gee-Chen, et al.
Published: (2022) -
Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
by: Salto-Tellez, M., et al.
Published: (2014) -
Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china
by: You, R., et al.
Published: (2021) -
Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
by: Chin, T.-M., et al.
Published: (2021)